XASX1AD
Market cap5mUSD
Dec 23, Last price
0.02AUD
1D
0.00%
1Q
-21.05%
Jan 2017
-90.85%
IPO
-94.24%
Name
Adalta Ltd
Chart & Performance
P/E
—
P/S
5.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
36.55%
Rev. gr., 5y
-13.26%
Revenues
2m
-49.91%
Net income
-5m
L+10.93%
CFO
-5m
L+2.49%
Earnings
Feb 25, 2025
Profile
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2016‑02 | 2015‑06 | |
| Income | |||||||||||
Revenues | 1,738 -49.91% | 3,469 25.99% | 2,754 -30.89% | ||||||||
Cost of revenue | 6,999 | 10,325 | 8,719 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (5,262) | (6,856) | (5,966) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (1,738) | (2,883) | (1,391) | ||||||||
Tax Rate | |||||||||||
NOPAT | (3,524) | (3,973) | (4,574) | ||||||||
Net income | (5,381) 10.93% | (4,851) -19.96% | (6,061) 7.69% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 5,122 | 1,141 | 4,472 | ||||||||
BB yield | -39.83% | -14.93% | -29.75% | ||||||||
| Debt | |||||||||||
Debt current | 1,525 | 4,014 | 2,390 | ||||||||
Long-term debt | 1,390 | 1,613 | |||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 142 | 15 | (1,613) | ||||||||
Net debt | (219) | (776) | (4,658) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (5,260) | (5,132) | (4,089) | ||||||||
CAPEX | (62) | (2) | (25) | ||||||||
Cash from investing activities | (62) | (2) | (25) | ||||||||
Cash from financing activities | 3,666 | 1,267 | 7,023 | ||||||||
FCF | (105) | (8,393) | (3,035) | ||||||||
| Balance | |||||||||||
Cash | 3,133 | 4,790 | 8,661 | ||||||||
Long term investments | |||||||||||
Excess cash | 3,047 | 4,616 | 8,523 | ||||||||
Stockholders' equity | 2,030 | 1,910 | 5,379 | ||||||||
Invested Capital | 2,847 | 8,043 | 4,025 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 494,600 | 318,292 | 278,410 | ||||||||
Price | 0.03 8.33% | 0.02 -55.56% | 0.05 -56.80% | ||||||||
Market cap | 12,860 68.34% | 7,639 -49.19% | 15,034 -49.16% | ||||||||
EV | 12,641 | 6,863 | 10,377 | ||||||||
EBITDA | (5,199) | (6,826) | (5,933) | ||||||||
EV/EBITDA | |||||||||||
Interest | 115 | 124 | 111 | ||||||||
Interest/NOPBT | |||||||||||